SLN · Silence Therapeutics Plc

Current Thesis

Silence Therapeutics’ post-readout continuation thesis has failed its published price test: the 2026-09-11 weekly close of $13.02 breached the $13.50 offering-price threshold. The underlying clinical argument remains the divesiran response reported on 2026-08-10, but that result does not reverse the market invalidation.

For this continuation leg, the narrative is dead — the September 11 close broke the condition specified in the September 5 research note. This classification concerns the market structure, not a finding that divesiran failed clinically. The remaining company argument is progression toward the guided first-half 2027 Phase 3 start, with zerlasiran development dependent on a third-party partner, according to the August 10 business update.

Bullish and bearish views on Silence Therapeutics Plc

The model's bull view on Silence Therapeutics Plc (SLN), in brief: The clinical endpoint was met. Silence’s 2026-08-10 SANRECO release reported an 88% response with divesiran versus 19% with placebo among 48 patients with polycythemia vera. The every-12-week group recorded an 81.3% response; this supports further testing, while the sample is… The bear view: The published threshold has failed. The adjusted market series records a $13.02 close on 2026-09-11, below the $13.50 weekly condition published on September 5. The continuation case is already invalidated; a lower replacement threshold would change the original test.… Both cases follow in full.

Bull Case

• The clinical endpoint was met. Silence’s 2026-08-10 SANRECO release reported an 88% response with divesiran versus 19% with placebo among 48 patients with polycythemia vera. The every-12-week group recorded an 81.3% response; this supports further testing, while the sample is too small to establish uncommon-event safety or commercial success. SANRECO release
• Financing supplied development capital. Company pricing and closing releases reported approximately $175 million in gross proceeds from an offering priced at $13.50 per American depositary share (ADS), closed on 2026-08-14. Gross proceeds do not establish current cash or a funded-through date; neither figure is established here.

Bear Case

• The published threshold has failed. The adjusted market series records a $13.02 close on 2026-09-11, below the $13.50 weekly condition published on September 5. The continuation case is already invalidated; a lower replacement threshold would change the original test.
• Cardiovascular evidence complicates the second asset. Novartis’s 2026-09-04 filing reported that pelacarsen lowered lipoprotein(a), or Lp(a), but missed its primary cardiovascular-outcomes endpoint. Increased uncertainty for zerlasiran partnering is an inference, not a reported negotiation outcome; a disclosed partner agreement committing to Phase 3 would contradict the inference that this result obstructs development. Novartis filing
• Full clinical disclosure remains undated. Silence’s 2026-08-10 release promised full SANRECO results at a future medical congress without naming a presentation date. The September conference schedule therefore does not establish a new clinical-data catalyst. SANRECO release

Setup & Price Structure

The supplied adjusted daily series records a 94.6% three-month price increase as of 2026-09-11, despite the close being 15.6% below the $15.43 trailing-year high. These measured figures show that a substantial preceding advance coexists with the failed $13.50 threshold. They do not establish a new support level.

The August 14 offering is observable issuance following the August 10 clinical announcement. It does not identify subsequent selling by recipients. William Blair reiterated its rating on 2026-09-10 without a numerical target listed in Stock Analysis’s analyst table, documenting continued analyst attention after the readout. Retail participation, short interest and distance above a rising moving average are not established by the available evidence, so crowding cannot be classified. Analyst record

Catalyst Calendar (next 30 days)

Both dates come from the company’s 2026-09-02 conference announcement. The September 9 scheduled appearance is elapsed; its content is not established here. No additional company-confirmed catalyst date in the next 30 days was verified.

Elapsed catalysts

• 2026-09-15 — H.C. Wainwright conference. Silence’s September 2 announcement schedules a fireside chat at 3:00 p.m. Eastern Time. A disclosed zerlasiran counterparty and development commitment would materially change the partnering evidence; the event announcement promises no clinical dataset. (passed 5d ago)
• 2026-09-16 — Morgan Stanley conference. The same announcement schedules a fireside chat at 8:30 a.m. Eastern Time. If both remaining appearances pass without a disclosed agreement or a dated clinical milestone, these events will not have supplied either form of confirmation. (passed 4d ago)

What Would Change Our Mind

The offering-price structure has already broken: a weekly close below $13.50 was the published thesis-break condition, and the 2026-09-11 close of $13.02 satisfied it. A subsequent recovery would not erase that outcome.

A renewed case would require separate evidence: a weekly close above the August offering price of $13.50 together with a disclosed zerlasiran development agreement or a company-dated divesiran milestone. That conditional recovery case would fail on a subsequent weekly close below $13.50. The August 10 clinical result alone does not establish that recovery.

Correlation Notes

SLN remains a single-name clinical-catalyst assessment; no synchronized peer-price series is supplied to support a group-move claim. The 2026-09-04 pelacarsen result supplies a specific link to zerlasiran through Lp(a), but it does not measure SLN’s price correlation with Novartis or Ionis and does not test divesiran’s polycythemia vera endpoint. The September 8 market headline followed the September 4 primary disclosure; it was not the trial’s announcement date. Novartis filing